Now more than before biotechnology and pharmaceutical companies are searching for ways to optimize their clinical development programs to ensure that clinical studies result in quality data accepted by regulatory agencies and are cost effective. Many companies positively consider Russia and Eastern Europe precisely for the reason of high patient availability translating into increased patient recruitment speed, excellent data quality, cost-effectiveness of clinical programs and data acceptability by FDA and EMEA.

ACCELL works with pharmaceutical, biotechnology and CRO clients and we know exactly what our clients are looking for: quality of service, excellence in client relations, high rate of patient recruitment, and cost effectiveness.

ACCELL @ BIO International Convention